1. Home
  2. IMOS vs TNDM Comparison

IMOS vs TNDM Comparison

Compare IMOS & TNDM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

IMOS

ChipMOS TECHNOLOGIES INC.

HOLD

Current Price

$42.29

Market Cap

1.3B

Sector

Technology

ML Signal

HOLD

Logo Tandem Diabetes Care Inc.

TNDM

Tandem Diabetes Care Inc.

HOLD

Current Price

$18.07

Market Cap

1.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
IMOS
TNDM
Founded
1997
2006
Country
Taiwan
United States
Employees
N/A
N/A
Industry
Semiconductors
Medical/Dental Instruments
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.3B
1.4B
IPO Year
2007
2013

Fundamental Metrics

Financial Performance
Metric
IMOS
TNDM
Price
$42.29
$18.07
Analyst Decision
Buy
Analyst Count
0
19
Target Price
N/A
$28.00
AVG Volume (30 Days)
61.6K
1.4M
Earning Date
05-14-2026
05-07-2026
Dividend Yield
1.49%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$1,014,736,000.00
Revenue This Year
$21.75
$8.11
Revenue Next Year
$4.21
$11.85
P/E Ratio
$158.35
N/A
Revenue Growth
N/A
7.93
52 Week Low
$15.06
$10.00
52 Week High
$51.08
$29.65

Technical Indicators

Market Signals
Indicator
IMOS
TNDM
Relative Strength Index (RSI) 51.58 37.30
Support Level $32.65 $17.90
Resistance Level $45.24 $21.68
Average True Range (ATR) 1.95 1.16
MACD -0.19 -0.11
Stochastic Oscillator 26.49 12.46

Price Performance

Historical Comparison
IMOS
TNDM

About IMOS ChipMOS TECHNOLOGIES INC.

ChipMOS TECHNOLOGIES Inc is engaged in the research, development, manufacturing, and sale of high-integration and high-precision integrated circuits and related assembly and testing services. The company's segments include Testing, Assembly, Testing, and Assembly for LCD, OLED, and other Display Panel Driver Semiconductors (LCDD), Bumping, and others. It derives a majority of its revenue from Taiwan followed by Japan, the People's Republic of China, Singapore, and others.

About TNDM Tandem Diabetes Care Inc.

Tandem Diabetes designs, manufactures, and markets durable insulin pumps for individuals with diabetes. The firm first entered this market in 2012 and has since introduced multiple generations of pumps leading to its current t:slim X2 device. The firm recently launched its smaller Mobi pump and continues to work on Tobi (a tubeless version of Mobi), and the Sigi tubeless patch pump. Nearly three-quarters of total revenue is derived from the US, with the remainder primarily from other developed nations. The pumps themselves generate just over half of total sales, and another one-third is from disposable infusion sets that need to be changed over every 2 to 3 days.

Share on Social Networks: